In a recent NOTW, I shared what I believed to be the three reasons behind the weakness (in relevance order): The narrative around oral GLP-1s Schotts weak FY 2026 guidance (shared early in December) Stevanatos low float (80% or so remains in the hands of the Stevanato family) #3 is what it is and we cant do much about it
Other values may be used to determine a precise concentration of a stock solution
It cannot establish both molecular identities, the declared ratio, net quantity, uniformity, aggregation, stability or microbiological quality
2.2 Mitochondrial Function & Bioenergetics 5 Amino 1 MQ plays a crucial role in enhancing mitochondrial bioenergetics, improving ATP production, and increasing fatty acid oxidation
Therefore, the majority of anecdotal evidence suggests using much lower doses for longer cycles of up to 8-12 weeks